Related references
Note: Only part of the references are listed.Multiple myeloma with central nervous system relapse
Philip A. Egan et al.
HAEMATOLOGICA (2020)
CD19-targeted chimeric antigen receptor (CAR) T cells in CNS relapsed acute lymphoblastic leukemia (ALL).
Haley Newman et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma
Adam D. Cohen et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma
Matthew J. Frigault et al.
BLOOD (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Margherita Norelli et al.
NATURE MEDICINE (2018)
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Theodoros Giavridis et al.
NATURE MEDICINE (2018)
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
Bianca D. Santomasso et al.
CANCER DISCOVERY (2018)
Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma
Jeremy S. Abramson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Donald M. O'Rourke et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
Juliane Gust et al.
CANCER DISCOVERY (2017)
Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice
Artur Jurczyszyn et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
Syed Abbas Ali et al.
BLOOD (2016)
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
Yongxian Hu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide
Alfred L. Garfall et al.
BLOOD (2016)
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Alfred L. Garfall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Juergen Scheller et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2011)
How do immune cells overcome the blood-brain barrier in multiple sclerosis?
Catherine Larochelle et al.
FEBS LETTERS (2011)
Multiple myeloma invasion of the central nervous system
KO Schluterman et al.
ARCHIVES OF NEUROLOGY (2004)
Share Paper
